For this reason, until a dedicated imaging technique with a specific tracer is available, such as Prostate-Specific Membrane Antigen (PSMA)-PET for prostate cancer, multimodality assessment staging is preferred to increase accuracy in those patients who are eligible for BSS [23]. Here, FOLH1 is linked to prostate cancer.